Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …

Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in
heavily pretreated patients with hematological malignancies. However, relapses occur and …

Recent reports on the impressive efficacy of adoptively transferred T cells to challenge
cancer in early phase clinical trials have significantly raised the profile of T cell therapy …

Background To simplify clinical scale lymphocyte expansions, we investigated the use of the
WAVE®, a closed system bioreactor that utilizes active perfusion to generate high cell …

Broader implementation of cell-based therapies has been hindered by the logistics
associated with the expansion of clinically relevant cell numbers ex vivo. To overcome this …

Harnessing the human immune system as a foundation for therapeutic technologies capable
of recognizing and killing tumor cells has been the central objective of anti-cancer …

Adoptive cell therapy of metastatic melanoma with autologous tumor infiltrating lymphocytes
(TIL) is clinically effective, but TIL production can be challenging. Here we describe a …

Background aims The high level of complexity of current Good Manufacturing Practice–
compliant methods of manufacturing hampers rapid and broad application of treatment with …

The many clinical trials currently in progress will likely lead to the widespread use of stem
cell‐based therapies for an extensive variety of diseases, either in autologous or allogeneic …